Information Provided By: 
Fly News Breaks for April 27, 2016
OPK
Apr 27, 2016 | 13:44 EDT
Ladenburg Thalmann analyst Kevin DeGeeter believes OPKO Health resubmission of the New Drug Application for Rayaldee, which he notes came roughly within the timeframe he expected, lifts a potential overhang on the stock. The acceptance of the resubmission and issuance of a new PDUFA date suggest the issues identified by FDA at the third party supplier was limited and a suitable plan has been communicated, DeGeeter tells investors. The analyst keeps a Buy rating and $20 price target on OPKO shares.
News For OPK From the Last 2 Days
There are no results for your query OPK
